Integrating real-world data from Brazil and Pakistan into the OMOP common data model and standardized health analytics framework to characterize COVID-19 in the Global South

Elzo Pereira Pinto Junior, Priscilla Normando, Renzo Flores-Ortiz, Muhammad Usman Afzal, Muhammad Asaad Jamil, Sergio Fernandez Bertolin, Vinicius de Araujo Oliveira, Valentina Martufi, Fernanda de Sousa, Amir Bashir, Edward Burn, Maria Yury Ichihara, Mauricio L. Barreto, Talita Duarte Salles, Daniel Prieto-Alhambra, Haroon Hafeez, and Sara Khalid

1Center of Data and Knowledge Integration for Health (Cidacs), Fiocruz—Brazil, Parque Tecnológico da Edf, Tecnocentro, R. Mundo, Salvador, BA 41745-715, Brazil, 2Shaukat Khanum Memorial Cancer Hospital and Research Centre, Johar Town, Lahore, 54840, Pakistan, 3Fundació Institut, Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, 587 08007, Spain, and 4Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Oxford, OX3 7LD, United Kingdom

Corresponding Author: Sara Khalid, BE, MSc (Oxon), DPhil, Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK; sara.khalid@ndorms.ox.ac.uk

Received 1 June 2022; Revised 16 August 2022; Editorial Decision 20 September 2022; Accepted 29 September 2022

ABSTRACT

Objectives: The aim of this work is to demonstrate the use of a standardized health informatics framework to generate reliable and reproducible real-world evidence from Latin America and South Asia towards characterizing coronavirus disease 2019 (COVID-19) in the Global South.

Materials and Methods: Patient-level COVID-19 records collected in a patient self-reported notification system, hospital in-patient and out-patient records, and community diagnostic labs were harmonized to the Observational Medical Outcomes Partnership common data model and analyzed using a federated network analytics framework. Clinical characteristics of individuals tested for, diagnosed with or tested positive for, hospitalized with, admitted to intensive care unit with, or dying with COVID-19 were estimated.

Results: Two COVID-19 databases covering 8.3 million people from Pakistan and 2.6 million people from Bahia, Brazil were analyzed. 109,504 (Pakistan) and 921 (Brazil) medical concepts were harmonized to Observational Medical Outcomes Partnership common data model. In total, 341,505 (4.1%) people in the Pakistan dataset and 1,312,832 (49.2%) people in the Brazilian dataset were tested for COVID-19 between January 1, 2020 and April 20, 2022, with a median [IQR] age of 36 [25, 76] and 38 (27, 50); 40.3% and 56.5% were female in Pakistan and Brazil, respectively. 1.2% percent individuals in the Pakistan dataset had Afghan ethnicity. In Brazil, 52.3% had mixed ethnicity. In agreement with international findings, COVID-19 outcomes were more severe in men, elderly, and those with underlying health conditions.

Conclusions: COVID-19 data from 2 large countries in the Global South were harmonized and analyzed using a standardized health informatics framework developed by an international community of health informaticians. This proof-of-concept study demonstrates a potential open science framework for global knowledge mobilization and clinical translation for timely response to healthcare needs in pandemics and beyond.
INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic placed an unprecedented burden on global healthcare systems, particularly in under-resourced communities. With a COVID-19 death rate of 289 people in every 100,000 in late 2021, Brazil was the third worst hit country in the world.\(^1,2\) South Asia is home to a quarter of the world’s population and was a COVID-19 hotspot: India had the second-highest caseload in the world and neighboring Pakistan the third-highest in Asia.\(^3\) South Asian ethnicity is associated with a high risk of severe COVID-19 and related mortality.\(^3,4\) However, there are little or no real-world COVID-19 data from South Asia or Brazil. As the pandemic continues, a full picture of COVID-19’s natural history, globally and in South Asia and Latin America, is needed.\(^5\)

Routinely collected health data originate from a variety of real-world healthcare settings and are often not recorded for research use. Globally, and particularly in resource-limited settings, there is a lack of standardized systems for curating and analyzing these heterogeneous data.\(^6\) Consequently it can be difficult to compare any resulting evidence, limiting the potential to impact health-care policies and interventions. There is therefore a need for data science ecosystems for data harmonization and related governance, standardized analytics and related capacity building, and evidence generation that is transparent, timely, and transportable across health settings.\(^7\)

The health informatics community has begun using trusted research environments and federated distributed data networks (FDNs), motivated by the need for accelerated knowledge mobilization and clinical translation in the COVID-19 pandemic.\(^8-11\) The Observational Health Data Sciences and Informatics (OHDSI) collaboration\(^12\) has led to the development of an open source FDN framework.\(^13-18\) It enables mapping of participating data sources to the Observational Medical Outcomes Partnership (OMOP) common data model (CDM), standardized analytical open-source tools that data partners can run locally on their mapped data, and aggregation of site-specific results via open access. This strategy has gained credibility as a best-practice approach for conducting rapid, transparent, and reproducible international research.\(^8\) It has been leveraged to generate observational evidence for COVID-19 and has impacted international clinical guidelines and regulatory safety.
However, health data sources and data partners from low- and middle-income country (LMIC) settings remain largely underrepresented in such endeavors.

In this article, we describe the harmonization of 2 health data-bases from Brazil and Pakistan to the OMOP CDM. We illustrate their use for describing COVID-19 patient characteristics in these 2 large Global South countries. The ultimate aim of this work is to demonstrate the implementation of an international distributed network analytics approach to accelerate the clinical translation and global knowledge mobilization.

What this study adds
The international OHDSI COVID-19 collaboration previously harmonized data from >500 million people, including >7 million people tested for COVID-19 and >1.2 million with COVID-19, from 16 databases in the United States, Europe, China, and South Korea, resulting in one of the largest multinational characterization studies to understand covariates, treatments, and outcomes related to COVID-19.27 Latin America and South Asia together represent a third of the world’s population but could not be included in the international efforts due to a lack of reliable data and health informatics infrastructure. This study adds, for the first time, a large Pakistani database from the Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) and Brazilian Health Surveillance Service Data for State of Bahia (Center for Health Data and Knowledge Integration CIDACS/IGM/FIOCRUZ) to the OHDSI-OMOP data network (Supplementary Figure S1). To our knowledge, these are the first OMOP-harmonized real-world datasets representing ethnically diverse populations in Latin America and South Asia.

MATERIALS AND METHODS
Overview of the Federated Data Network
This work adopted a distributed FDN framework designed for rapid and reproducible research and knowledge exchange, using the OMOP CDM (Figure 1). The OMOP CDM has been developed to work with a wide range of routinely collected health-care data;14–16 numerous databases from North America, Europe, and beyond have been mapped to it.24,25,28,29 The OMOP CDM has also been used to inform several studies relating to the COVID-19 pandemic.17,19–34 The FDN design allows for accelerated analytics with the same analysis code being run by each data partner and aggregated results shared, without any need to share patient-level data between data partners.

OMOP mapping: extract, transform, and load
OMOP is an open-source CDM standard for harmonizing the structure and semantic representation of observational data.16 It follows a person-level relational database design to facilitate analysis of longitudinal person-level data such as clinical (eg, symptoms, diagnoses, drugs, procedures, devices, measurements, and text notes) and health system data (eg, healthcare provider, care site, and costs) that are organized into a set of predefined tables.3 The use of the OMOP CDM by participating researchers enables studies to be consistently developed, executed, and replicated across collaborator sites. The source data are extracted, transformed, and loaded (ETL) to map or conform it to the OMOP CDM.16 Over 3000 quality control checks on plausibility, conformance, and completeness assess whether the mapped database is fit for use. Any errors identified during quality control are addressed by updating the ETL where possible.16 A summary of OHDSI tools used for OMOP mapping is presented in Supplementary Appendix SA; full details can be found in Ref.16

Pakistan database
SKMCH&RC (www.shaukatkhanum.org.pk) is a 195-bed secondary and tertiary care hospital network in Pakistan that provides cancer and noncancer care and acts as a regional hub for COVID-19 cases. Its hospital information system contains electronic medical records for over 8.3 million people (52.7% female). This includes de-identified patient-level data on sociodemographics, laboratory

Figure 1. Schematic structure of the federated data network developed by the Observational Health Data Sciences and Informatics (OHDSI) community for standardized health analytics using the OMOP common data model (CDM). OMOP: Observational Medical Outcomes Partnership.
results, clinical diagnoses (from on-site and community diagnostic laboratories), outcomes, prescriptions, hospital in-patient procedures, and mortality from December 1994 to present (June 1, 2022). All COVID-19 records to date have been mapped to the OMOP-CDM. The mapped dataset is hereafter referred to as the SKMCH&RC COVID-19 database.

Brazil database
CIDACS-FIOCRUZ (www.cidacs.bahia.fiocruz.br) is a center for big health data linkage in Brazil. After the onset of the COVID-19 pandemic, CIDACS-FIOCRUZ developed a COVID-19 data integrated platform that contains aggregate and individual-level socioeconomic and demographic indicators extracted from the COVID-19 surveillance database for the State of Bahia, which covers a population of 15 million people (Supplementary Figure S5). It includes data on patient self-reported compulsory notifications of severe cases, hospitalizations, and deaths due to COVID-19 (SRAG), mild and moderate cases (ESUS), laboratory data (GAL), and vaccination data (VAC). This linked dataset, hereafter referred to as the CIDACS-FIOCRUZ COVID-19 database, contains 7,585,719 observations with data on age, sex, ethnicity, symptoms, outcome of suspected cases (hospitalization, intensive care unit [ICU] admission, death, and use of mechanical ventilator), observation period, and comorbidities at the time of notification.

Characterization of COVID-19

Study settings
Participants. All individuals who were tested for COVID-19 on or after January 1, 2020 (Brazil) and on or after March 1, 2020 (Pakistan) until April 30, 2022 were included.

Study cohorts. Five COVID-19-related cohorts were considered:

1. those in the general population tested for COVID-19,
2. those who tested positive for or were diagnosed with COVID-19,
3. those hospitalized with COVID-19, within 30 days of a positive test or diagnosis of COVID-19,
4. those admitted to ICU with COVID-19, within 30 days of a positive test or diagnosis of COVID-19,
5. those who died with COVID-19 within 30 days of positive test or diagnosis of COVID-19.

The cohorts were not mutually exclusive. Detailed cohort definitions may be found in Supplementary Appendix SA.

Baseline characteristics. Sociodemographics (age, sex, and ethnicity) and medical history (body mass index [BMI], smoking status, and available comorbidities) were included.

Statistical analysis
The baseline characteristics of the participants in each of the study cohorts were calculated for the Pakistan and Brazil COVID-19 cohorts, with counts and percentages for categorical variables and median and interquartile ranges (IQR) for continuous variables. For variables with missing data, estimates were based on cases without missingness (complete-case). BMI was not available in Pakistan data, whereas smoking status was not available in Brazil data. To plot the distribution of COVID-19 cases over time, the number of cases per month was calculated for each cohort, counted at the time an individual entered a given cohort.

The Brazil and Pakistan COVID-19 datasets were analyzed independently and simultaneously. At the time of writing, all COVID-19 concepts from the Brazilian CIDACS-FIOCRUZ COVID-19 database had been mapped to the OMOP CDM via ETL implementation, however, mapping of patient-level records was yet to be done. Baseline characterization was therefore based on the source CIDACS-FIOCRUZ database. In contrast as the Pakistani SKMCH&RC COVID-19 database was fully mapped to the OMOP CDM, analyses were conducted using its CDM version.

RESULTS

Harmonization to OMOP CDM
A total of 109,504 medical concepts in the SKMCH&RC COVID-19 dataset were mapped from the source database to 108,684 matching concepts in the OMOP CDM (summarized in Table 1). In the CIDACS-FIOCRUZ COVID-19 dataset, 921 concepts were mapped to 915 matching OMOP concepts (summarized in Table 2). This concept mapping allowed source concepts from hundreds of tables to be matched to a universal set of 8 domains in the OMOP CDM: “Provider”, “Measurement”, “Specimen”, “Procedure”, “Device”, “Drug Exposure”, “Condition”, and “Unit of Measurement” (Tables 1 and 2). For example, the SKMCH&RC COVID-19 CDM included 33.9 million laboratory results (“Measurement” table) for 349,879 patient records (“Person” table) collected from 357 sites around the country (“Location” table) as

Table 1. Summary of SKMCH&RC COVID-19 (Pakistan) database concepts mapped to the OMOP CDM

| Source domain             | CDM domain | Number of source concepts | Number of mapped concepts | Number of unmapped concepts |
|---------------------------|------------|---------------------------|---------------------------|----------------------------|
| Doctor specialty          | Provider   | 57                        | 57                        | 0                          |
| Pathology test            | Measurement| 591                       | 591                       | 0                          |
| Pathology specimen        | Specimen   | 484                       | 463                       | 19                         |
| Pathology text results    | Measurement| 1028                      | 758                       | 270                        |
| Procedures                | Procedure  | 4986                      | 4977                      | 9                          |
| Surgical supplies         | Device     | 1314                      | 1281                      | 33                         |
| Vital signs               | Measurement| 14                        | 14                        | 0                          |
| Drug route                | Drug exposure| 31                        | 30                        | 1                          |
| Drug generics             | Drug exposure| 2643                      | 2299                      | 344                        |
| ICD codes                 | Condition  | 97,808                    | 97,808                    | 0                          |
| Unit of measurement       | Used in multiple domains| 548                       | 404                       | 144                        |
| **Total**                 |            | **109,504**               | **108,684**               | **820**                    |

CDM: common data model; OMOP: Observational Medical Outcomes Partnership.
shown in Supplementary Table S1. Although most of the concepts in the source domains had matching concepts in the corresponding CDM domains, 820 (0.7%) Pakistani concepts and 6 (0.6%) Brazilian concepts did not have matching concepts and were not mapped. The 820 unmapped concepts in Table 1 correspond to 6.46%, 0.66%, and 9.96% of the “Drug exposure,” “Measurement,” and “Procedure” domains, respectively.

Supplementary Figures S2 and S3 summarize the ETL stages of the harmonisation process for the SKMCH&RC (Pakistan) and CIDACS-FIOCRUZ (Brazil) COVID-19 datasets, respectively. The steps to translate or map source data to OMOP CDM were customized for each database. As the SKMCH&RC COVID-19 database was available as a pre-existing electronic health record database generated by SKMCH&RC’s hospital information system, ETL was implemented directly (see figure for example of ETL code mapping). Before ETL could be applied to the CIDACS-FIOCRUZ database, relevant COVID-19 fields had to first be extracted from 2 heterogeneous source datasets (ESUS and SRAG).

Supplementary Figure S4 shows the results for 3486 data quality checks performed on the SKMHR&C COVID-19 database within the FDN framework for assessment of the ETL process. A total of 12 errors were found in the type “measurement unit not found” and “unmapped concept” with an overall pass rate of 100% (with regards to plausibility, conformance, and completeness) these errors did not impact the study.

Figure 2 shows an example of the ETL concept mapping process for the Pakistan database.

COVID-19 characterization
Pakistan
The SKMCH&RC database contained information on a total of 8 334 767 unique individuals, of whom 341 505 were tested for COVID-19 between March 1, 2020 and April 30, 2022. Table 3 summarizes the baseline characteristics of people who were tested, tested positive, were hospitalized, admitted to ICU, and who died. Figure 3 shows the distribution of sex and ethnicity in the general tested population. For example, 28% of those hospitalized, 33% of those admitted to ICU, and 32% of those who died had diabetes, compared with 3.6% in the general population and 4% of those who tested positive. Heart disease was present in 48% of those hospitalized, 54% of those admitted to ICU, and 50% of those who died, compared with 3.6% in the general population and 4% of those who tested positive.

Table 4 summarizes the baseline characteristics of those who were tested, tested positive, hospitalized, admitted to ICU, and who died. A smaller proportion of male participants were tested (43.5%) and tested positive for COVID-19 (45%), whereas a greater proportion of male participants were hospitalized (57%), admitted to ICU (57%), or died (55%), compared with female participants. The average (median [IQR]) age of those tested in the general population was 38 years [27–50], whereas those who died (69 years [56–80]), were admitted to ICU (62 years [48–75]), or were hospitalized (48 years [33–64]) were older, for both men and women (Figure 4). Comorbidities followed a similar trend with diabetes, hypertensive disorder, and renal impairment in 23.08%, 26.5%, and 32.48% of those who died in hospital compared with 1%, 1.33%, and 0.28% of the same in the general tested population. Figure 6 shows the distribution of COVID-19 cases over time.

Brazil
The CIDACS-FIOCRUZ database contained information on 2 669 866 unique individuals from the general population, of whom 1 312 832 (49.2%) met the inclusion criteria and had a valid COVID-19 test. In total, 752 699 (57.3%) tested positive between January 1, 2020 and April 30, 2022. In those tested, 56.5% were female; 52.3% had mixed, 11.1% White, 7.4% Black, 5% Asian, and 0.2% Indigenous ethnicity; ethnicity was missing for 24% (Figure 3).

Table 4 summarizes the baseline characteristics of those who were tested, tested positive, hospitalized, admitted to ICU, and who died. A smaller proportion of male participants were tested (43.5%) and tested positive for COVID-19 (45%), whereas a greater proportion of male participants were hospitalized (57%), admitted to ICU (57%), or died (55%), compared with female participants. The average (median [IQR]) age of those tested in the general population was 38 years [27–50], whereas those who died (69 years [56–80]), were admitted to ICU (62 years [48–75]), or were hospitalized (58 years [45–72]) were much older, for both men and women (Figure 5). Comorbidities followed a similar trend. For example, 28% of those hospitalized, 33% of those admitted to ICU, and 32% of those who died had diabetes, compared with 3.6% in the general population and 4% of those who tested positive. Heart disease was present in 48% of those hospitalized, 54% of those admitted to ICU, and 50% of those who died, compared with 5.8% of the general population and 6.5% of those who tested positive.
rapid, reproducible, and reliable evidence generation. There is a growing body of evidence to suggest that such translational research may be possible with heterogeneous yet harmonized, quality-controlled, well-governed real-world health data using standardized approaches such as distributed federated data networks.\textsuperscript{17,19–34} We applied one such framework (OMOP) developed by a global health informatics community (OHDSI) to health data from 2 geographically and sociodemographically diverse databases. Key pillars of the OMOP framework were leveraged namely data governance, data harmonization, and standardized analytics for transparent and fair health informatics.

Harmonization to OMOP CDM — Insights
COVID-19 data from Brazil and Pakistan collected from and representative of different health-care settings were mapped to the OMOP CDM. The data from Brazil were generated from a bespoke patient-reported COVID-19 notification system that was developed for surveillance purposes and later linked with hospitalization and vaccination records from one state within Brazil. The data from Pakistan were extracted from an existing hospital information system spread across Pakistan. Despite the heterogeneity in the source data, it was possible to harmonize the data to a universal data vocabulary set. The ETL process for mapping to OMOP was tailored to each source database, to deal with their differing levels of complexity.

The Brazilian dataset was comparatively more complex and the mapping process correspondingly more time-consuming than the Pakistan dataset (Supplementary Figure S6). It involved the linkage of 181 tables retrieved from separate administrative datasets (SRAG, ESUS, GAL, and VAC) of the Brazilian Ministry of Health COVID-19 Surveillance system, which in itself was developed through a modification of the Brazil Influenza Surveillance System for pandemic response. In addition, there was not a unique key to merge the separate datasets. A deterministic linkage algorithm had to be derived using a person identification variable (comprising 5 identifiers), common sociodemographic variables such as age, sex, and municipality of residence. These variables are recorded under different names in the separate datasets with differing degrees of completeness. A key lesson learnt therefore was the impact of data complexity on speed and scale of research.

Several generalizable insights may also be drawn from this work. When mapping routinely collected datasets to a common model such as OMOP CDM, it is necessary to conduct feasibility of datasets suitable for real-world evidence generation, assessment of variables to be used for linkage, and determination of validated linkage algorithms if required.
Figure 3. Distribution of sex (left) and ethnicity (right) in the general population tested for COVID-19, in the Pakistan (top) and Brazil (bottom) datasets. A matching concept for ethnicity/race = “Afghan” was not available in the OMOP CDM at the time of writing. The 1.2% of Afghan individuals in the Pakistan database are therefore labeled as “no matching concept.” CDM: common data model; COVID-19: coronavirus disease 2019; OMOP: Observational Medical Outcomes Partnership.

Table 3. Baseline characteristics of the COVID-19 study cohorts (PAKISTAN)

| Variable                  | Tested population (ie, general population) | Outpatient COVID-19 diagnosis or positive test | Hospitalized with COVID-19 | ICU admission with COVID-19 | COVID-19 death |
|---------------------------|--------------------------------------------|-----------------------------------------------|----------------------------|----------------------------|----------------|
| N                         | 341,505                                    | 88,771                                        | 447                        | 33                         | 117            |
| Age (median [IQR])        | 36 [25–76]                                 | 40 [25–76]                                   | 48 [33–64]                 | 52 [22–63]                 | 53 [41–65]     |
| Age group (n [%])         |                                            |                                               |                            |                            |                |
| Under 20                  | 35,090 (10.3)                              | 6,453 (7.3)                                  | 68 (15.2)                  | 3 (9.1)                    | 10 (8.6)       |
| 20–29                     | 72,958 (21.4)                              | 16,064 (18.1)                                | 39 (8.7)                   | 3 (9.1)                    | 3 (2.6)        |
| 30–39                     | 86,984 (25.5)                              | 20,748 (23.4)                                | 61 (13.7)                  | 6 (18.2)                   | 14 (12.0)      |
| 40–49                     | 57,221 (16.8)                              | 14,931 (16.8)                                | 73 (16.3)                  | 1 (3.0)                    | 20 (17.0)      |
| 50–59                     | 42,592 (12.5)                              | 13,284 (15.0)                                | 93 (20.8)                  | 10 (10.3)                  | 25 (21.4)      |
| 60–69                     | 29,678 (8.1)                               | 10,620 (12.0)                                | 81 (18.1)                  | 9 (27.3)                   | 28 (24.0)      |
| 70–79                     | 13,227 (3.9)                               | 5,137 (5.8)                                  | 27 (6.0)                   | 1 (3.0)                    | 12 (10.3)      |
| 80 or older               | 3,755 (1.1)                                | 1,534 (1.7)                                  | 5 (1.1)                    | 0 (0)                      | 4 (3.4)        |
| Sex: male (n [%])         | 204,125 (59.7)                             | 50,964 (54.4)                                | 239 (53.5)                 | 17 (51.5)                  | 64 (54.7)      |
| Smoking status (n [%])    |                                            |                                               |                            |                            |                |
| Current smoker            | 197 (0.06)                                 | 49 (0.06)                                    | 14 (3.13)                  | 0 (0)                      | 3 (2.56)       |
| Ex-smoker                 | 414 (0.12)                                 | 99 (0.11)                                    | 26 (5.82)                  | 2 (6.06)                   | 6 (5.13)       |
| Nonsmoker                 | 4,225 (1.24)                               | 1,040 (1.17)                                 | 249 (55.70)                | 14 (42.42)                 | 56 (47.86)     |
| Missing                   | 336,669 (98.5)                             | 87,583 (98.6)                                | 158 (35.4)                 | 17 (51.5)                  | 52 (44.44)     |
| BMI (median [IQR])        | NA                                         | NA                                            | NA                         | NA                         | NA             |
| Comorbidities (n [%])     |                                            |                                               |                            |                            |                |
| Diabetes mellitus         | 3,432 (1)                                  | 1,155 (1.30)                                 | 76 (17)                    | 12 (36.36)                 | 27 (23.08)     |
| Heart disease             | 743 (0.22)                                 | 243 (0.27)                                   | 19 (4.25)                  | 4 (12.12)                  | 7 (5.98)       |
| Hypertensive disorder     | 4,525 (1.33)                               | 1,388 (1.56)                                 | 100 (22.37)                | 12 (36.36)                 | 31 (26.50)     |
| Renal impairment          | 973 (0.28)                                 | 207 (0.23)                                   | 82 (18.34)                 | 13 (39.39)                 | 38 (32.48)     |
| Cancer                    | 5,868 (1.02)                               | 1,321 (1.49)                                 | 314 (70.25)                | 21 (63.64)                 | 66 (56.41)     |
| Dementia                  | 6 (0)                                      | 2 (0)                                        | 1 (0.22)                   | 0 (0)                      | 1 (0.85)       |
| Autoimmune disease        | 1 (0)                                      | 1 (0)                                        | 0 (0)                      | 0 (0)                      | 0 (0)          |
| COPD                      | 57 (0.02)                                  | 14 (0.02)                                    | 5 (1.12)                   | 2 (6.06)                   | 3 (2.56)       |
| Asthma                    | 316 (0.09)                                 | 109 (0.12)                                   | 13 (2.90)                  | 0 (0)                      | 3 (2.56)       |
| Obesity                   | NA                                         | NA                                            | NA                         | NA                         | NA             |

BMI: body mass index; ICU: intensive care unit; IQR: interquartile range; COVID-19: coronavirus disease 2019.
Figure 4. Distribution of age by sex in each COVID-19 cohort (PAKISTAN). COVID-19: coronavirus disease 2019.
Inevitably routine data may suffer from incompleteness. Data sources must therefore be sufficiently sized to maintain the ability to generate reliable knowledge. For instance, the data of birth was missing from 750 individuals in the Pakistan data; therefore, their records could not be included in the analysis.

Another key learning was the value of capacity building. A successful health informatics ecosystem depends on cross-collaboration between clinicians, data scientists, researchers, IT specialists, and information governance experts. Ultimately, a number of training needs were identified in order to build capacity for North-South information governance experts. Ultimately, a number of training needs were identified in order to build capacity for North-South research. For example, this study resulted in a real-world data science knowledge exchange programme between the research teams in Brazil, Pakistan, Spain, and the UK.

**COVID-19 characterization — Insights**

Patient characteristics demonstrated the richness of data with respect to sociodemographic and clinical information. The Brazil database included individuals with Asian, Black, Indigenous, Mixed, and White ethnicities. Although most of the people in the Pakistan database were of Pakistani ethnicity, around 1.2% had Afghan ethnicity. To our knowledge, this is the first record of Afghan ethnicity database included individuals with Asian, Black, Indigenous, Mixed, and White ethnicities. Although most of the people in the Pakistan database were of Pakistani ethnicity, around 1.2% had Afghan ethnicity. To our knowledge, this is the first record of Afghan ethnicity which the data originate, one being secondary care data and the other population-based surveillance data. For example ethnicity was considered as fully representative. The Brazil database for example contained individuals from one state of Brazil (Bahia). The Pakistan database contained individuals from all over Pakistan, however, only those who sought healthcare within the SKMHR&C hospital network, via one of 2 pathways: (1) tested for COVID-19 in SKMHR&C hospital and admitted for COVID-19 or cancer care and (2) tested for COVID-19 in an SKMHR&C community or on-site diagnostic lab but not admitted to the hospital. For the latter group, although complete COVID-19 diagnostic data were available, data capture on medical history was limited, potentially explaining the dominance of cancer as the main comorbidity in the characterization.

As with any routinely collected data not collected for health research by design, some of the information was incomplete. There were differences in the data capture and coverage from both settings; which in turn reflects the heterogeneity of the underlying settings in which the data originate, one being secondary care data and the other population-based surveillance data. For example ethnicity was missing in nearly a quarter of the individuals from Brazil. BMI was recorded for Brazilian individuals but not for Pakistan individuals, and vice versa for smoking. While data harmonization can improve usability and comparability of available data, the need for better collection at source remains.

Through this work, the 2 databases joined a growing health informatics community of over 100 international observational OMOP-mapped databases. By “speaking the same language” afforded by common data models such as OMOP, they can be used

### Table 4. Baseline characteristics of the COVID-19 study cohorts (BRAZIL)

| Variable                          | Tested population (ie, general population) | Outpatient COVID-19 diagnosis or positive test | Hospitalized with COVID-19 | ICU admission with COVID-19 | COVID-19 death |
|-----------------------------------|-------------------------------------------|-----------------------------------------------|----------------------------|-----------------------------|----------------|
| N                                 | 1 312 832                                  | 752 699                                       | 34 699                     | 17 041                      | 13 877         |
| Age (median [IQR])                | 38 [27–50]                                 | 39 [29–51]                                   | 58 [45–72]                 | 62 [48–75]                  | 69 [56–80]     |
| Age group (n [%])                 |                                            |                                              |                            |                             |                |
| Under 20                          | 127 765 (9.7)                              | 54 277 (7.2)                                 | 745 (2.1)                  | 271 (1.6)                   | 77 (0.6)       |
| 20–29                            | 257 065 (20)                               | 137 443 (18)                                 | 1044 (3.0)                 | 376 (2.2)                   | 190 (1.4)      |
| 30–39                            | 317 037 (24)                               | 187 526 (25)                                 | 3809 (11)                  | 1484 (8.7)                  | 649 (4.7)      |
| 40–49                            | 264 994 (20)                               | 162 490 (22)                                 | 5791 (17)                  | 2472 (15)                   | 1374 (9.9)     |
| 50–59                            | 167 933 (13)                               | 105 102 (14)                                 | 6653 (19)                  | 3118 (18)                   | 2075 (15)      |
| 60–69                            | 94 587 (7.2)                               | 57 971 (7.7)                                 | 6276 (18)                  | 3339 (20)                   | 2735 (20)      |
| 70–79                            | 51 002 (3.9)                               | 30 199 (4.0)                                 | 5451 (16)                  | 3142 (18)                   | 3138 (23)      |
| 80 or older                      | 32 449 (2.5)                               | 17 691 (2.4)                                 | 4930 (14)                  | 2839 (17)                   | 3639 (26)      |
| Sex: male (n [%])                |                                            |                                              |                            |                             |                |
| 0–9                              |                                            |                                              |                            |                             |                |
| 10–19                            |                                            |                                              |                            |                             |                |
| 20–29                            |                                            |                                              |                            |                             |                |
| 30–39                            |                                            |                                              |                            |                             |                |
| 40–49                            |                                            |                                              |                            |                             |                |
| 50–59                            |                                            |                                              |                            |                             |                |
| 60–69                            |                                            |                                              |                            |                             |                |
| 70–79                            |                                            |                                              |                            |                             |                |
| 80 or older                      |                                            |                                              |                            |                             |                |
| BMI (median [IQR])               |                                            |                                              |                            |                             |                |
| Diabetes mellitus                | 46 944 (3.6)                               | 30 368 (4.0)                                 | 9644 (28)                  | 5573 (33)                   | 4494 (32)      |
| Heart disease                    | 76 191 (5.8)                               | 48 762 (6.5)                                 | 16 337 (48)                | 9260 (54)                   | 6904 (50)      |
| Renal impairment                 | 6585 (0.5)                                 | 4041 (0.5)                                   | 1647 (4.7)                 | 1148 (6.7)                  | 977 (7.0)      |
| Cancer                           | 665 (<0.1)                                 | 464 (<0.1)                                   | 353 (1.0)                  | 203 (1.2)                   | 225 (1.6)      |
| Dementia                         | 415 (<0.1)                                 | 243 (<0.1)                                   | 199 (0.6)                  | 111 (0.7)                   | 120 (0.9)      |
| Autoimmune disease               | 10 035 (0.8)                               | 3374 (0.7)                                   | 1369 (3.9)                 | 721 (4.2)                   | 769 (5.5)      |
| Respiratory disease              | 23 618 (1.8)                               | 12 478 (1.7)                                 | 2169 (6.3)                 | 1224 (7.2)                  | 1013 (7.3)     |
| Obesity                          | 14 440 (1.1)                               | 10 386 (1.4)                                 | 4075 (12)                  | 2429 (14)                   | 1348 (9.7)     |

BMI: body mass index; ICU: intensive care unit; IQR: interquartile range; COVID-19: coronavirus disease 2019.
Figure 5. Distribution of age by sex in each COVID-19 cohort (BRAZIL). COVID-19: coronavirus disease 2019.
together to address critical health questions and generate both locally and globally relevant knowledge. Once data are mapped to a common data model, data partners in the FDN can run standardized analytical packages on their databases and contribute the results without needing to share patient-level data.

One of the key merits of the FDN framework approach is geographical and clinical scalability. Health data from anywhere in the world may be mapped to the OMOP CDM. Once harmonized, the data can support any clinical research through a standardized analytical pipeline that offers existing tools for causal inference, estima-
tion, and prediction, for example. The FDN used here has underlying data governance, open science, and capacity-building mechanisms, which make it well-suited to pandemic preparedness and response. As a result, it has been applied extensively in the COVID-19 response, including guidelines on COVID-19 drug safety and vaccine safety.\textsuperscript{17,19–34} Such an approach could be particularly well suited to LMIC settings as re-use of existing data can provide a cheaper alternative to or complement randomized clinical trials, which are generally time-consuming and expensive. It may also contribute to moving away from health research silos.

CONCLUSION

This paper describes the process of mapping two health databases from Latin America and South Asia to the OMOP CDM for COVID-19 characterization. Future work includes scalability and capacity-building. This study is hoped to contribute to an ecosystem for observational evidence generation in 2 large regions in Latin America and South Asia to inform health interventions and policymaking for and beyond the COVID-19 pandemic.

FUNDING

This publication is based on research funded in part by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.

AUTHOR CONTRIBUTIONS

All authors contributed equally to this work in accordance with ICMJE criteria for authorship; PN, EP, HH, DPA, TDS, MB, and SK were responsible for study conception and design; EP, PN, RFO, MUA, MAJ, SF, VAO, VF, FS, AB, EB, MYI, VM, and SK were involved in data curation, analysis, and interpretation; EP, PN, RFO, MUA, MAJ, SF, VAO, VF, FS, AB, EB, MYI, VM, DPA, and SK contributed to writing, reviewing and approving this manuscript, and are accountable for this work. SK has overall responsibility for this work.

SUPPLEMENTARY MATERIAL

Supplementary material is available at Journal of the American Medical Informatics Association online.

ACKNOWLEDGMENTS

The authors would like to acknowledge editing support by Dr Jennifer A de Beyer, Dr Marta Pineda, and Ms Emma Jackson at Centre for Statistics in Medicine, University of Oxford.

CONFLICT OF INTEREST STATEMENT

SK has received research grant funding from the UKRI and Alan Turing Institute outside this work. SK and DPA’s research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. SK and DPA’s department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortia, and Synapse Management Partners have supported training programs organized by DPA’s department and open for external participants organized by his department outside submitted work.

DATA AVAILABILITY

All study documents, including the study protocol and R code, are publicly available on request via GitHub (https://github.com/ohdsi-studies). Results for each of the databases participating in the study can be combined in an R Shiny application and then uploaded to the publicly available OHDSI Viewer Dashboard. The OHDSI tools involved in the prediction pipeline are regularly updated and revised versions are maintained on the Git Hub. The OHDSI Forum is open for all to join, contribute to the development and use of tools, and cocreate scientific questions.

REFERENCES

1. Hannah R, Edouard M, Lucas R, et al. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus. Accessed April 20, 2022.
2. John Hopkins University Coronavirus Resource Centre. https://coronavirus.jhu.edu/. Accessed April 20, 2022.
3. Pareek M, Bangash MN, Pareek N, et al. Ethnicity and COVID-19: an urgent public health research priority. Lancet 2020; 395 (10234): 1421–2.
4. Harrison EM, Docherty AB, Barr B, et al. Ethnicity and outcomes from COVID-19: the ISARIC CCCP-UK prospective observational cohort study of hospitalised patients. Preprints with The Lancet 2020.
5. Bakken S. Informatics is a critical strategy in combating the COVID-19 pandemic. J Am Med Inform Assoc 2020; 27 (6): 843–4.
6. Obeis J, Tarczy-Hornoch P, Harris PA, et al. Sustainability considerations for clinical and translational research informatics infrastructure. J Clin Transl Sci 2018; 2 (5): 267–75.
7. Fernandez-Luque L, Kushniruk AW, Georgiou A, et al. Evidence-based health informatics as the foundation for the COVID-19 response: a joint call for action. Methods Inf Med 2021; 59 (6): 183–92.
8. Platt RW, Platt R, Brown JS, Henry DA, Klungel OH, Sussa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol Drug Saf 2019; 29 (S1): 3–7.
9. Kent S, Burn E, Dawoud D, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics 2021; 39 (5): 273–85.
10. European Medicines Agency. A Common Data Model for Europe?—Why? Which? How? 2018. https://www.ema.europa.eu/en/documents/report/common-data-model-europe-why-which-how-workshop-report_en.pdf. Accessed April 20, 2022.
11. Brown JS, Holmes JH, Shah K, et al. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care 2010; 48 (6 Suppl): S45–51.
12. Observational Health Data Sciences and Informatics. https://ohdsi.org/who-we-are/collaborators/. Accessed April 20, 2022.
13. Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574–8.
14. Voss EA, Makadza R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015; 22 (3): S53–64.
15. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stange PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012; 19 (1): 54–60.
16. “The Book of OHDSI” Observational Health Data Sciences and Informatics. 2020. https://ohdsi.github.io/TheBookOfOhdsi/. Accessed December 7, 2020.
17. Burn E, You SC, Sena AG, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. *Nat Commun* 2020; 11 (1): 5009.

18. Reps J, Schuemie M, Suchard M, et al. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. *J Am Med Inform Assoc* 2018; 25 (8): 969–75.

19. COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine. European Medicines Agency, Amsterdam, The Netherlands. https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine. Accessed April 23, 2020.

20. Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. *Lancet Rheumatol* 2020; 2 (11): e698–711.

21. EMA COVID-19 Vaccines Authorised. https://www.ema.europa.eu/en/news/covid-19/treatments-vaccines-covid-19. Accessed April 20, 2022.

22. Lai LYH, Golozar A, Sena A, et al. Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States. *medRxiv* 2020. DOI: 10.1101/2020.05.26.20112649.

23. Golozar A, Lai LY, Sena AG, et al. Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis. *medRxiv* 2020. DOI: 10.1101/2020.10.13.20211821.

24. Lane JCE, Weaver J, Kostka K, et al. Risk of depression, suicidal ideation, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multi-national network cohort study. *medRxiv* 2020. DOI: 10.1101/2020.07.17.20156039.

25. Khalid S, Yang C, Blacketer C, et al. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. *Compt Methods Programs Biomed* 2021; 106:394.

26. Prats-Uribe A, Sena AG, Lai LYH, et al. Heterogeneity and temporal variation in the management of COVID-19: a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America. *medRxiv* 2020. DOI: 10.1101/2020.09.15.20195545.

27. Reps JM, Kim C, Williams RD, et al. Can we trust the prediction model? Demonstrating the importance of external validation by investigating the COVID-19 Vulnerability (C-19) Index across an international network of observational healthcare datasets. *medRxiv* 2020. DOI: 10.1101/2020.06.15.21030328.

28. Morales DR, Conover MM, You SC, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. *Lancet Digit Health* 2020; 3 (2): e98–114.

29. Prats-Uribe A, Fortin S, Weinstein R, et al. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. *medRxiv* 2020. DOI: 10.1101/2020.09.23.20199463.

30. Kostka K, Duarte-Salles T, Khalid S, et al. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. *Clin Epidemiol* 2022; 14: 369–84.

31. Williams RD, Markus AF, Yang C, et al. Seek COVER: development and validation of a personalized risk calculator for COVID-19 outcomes in an international network. *medRxiv* 2020. DOI: 10.1101/2020.05.26.2112649.